DUBLIN–(BUSINESS WIRE)–The “Integrin
Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline
Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) –
Integrin beta-3 (3) or CD61 is a protein that in humans is encoded by
the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain
in platelets. It is a receptor for cytotactin, fibronectin, laminin,
matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin,
thrombospondin, vitronectin and von Willebrand factor. Activation of
integrin alpha-IIb/beta-3 leads to platelet interaction through binding
of soluble fibrinogen. This leads to rapid platelet aggregation which
physically plugs ruptured endothelial surface.
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
pipeline Target constitutes close to 24 molecules. Out of which
approximately 19 molecules are developed by companies and remaining by
the universities/institutes. The molecules developed by companies in
Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and
15 respectively. Similarly, the universities portfolio in Preclinical
stages comprises 5 molecules, respectively.
This report covers products from therapy areas Oncology, Ophthalmology,
Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal,
Infectious Disease and Immunology which include indications Breast
Cancer, Wet (Neovascular / Exudative) Macular Degeneration, Coronary
Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Nephropathy,
Glioblastoma Multiforme (GBM), Metastatic Melanoma, Pancreatic Cancer,
Persistent Corneal Epithelial Defects, Wounds, Diabetic Macular Edema,
Escherichia Coli Septicaemia, Ischemic Stroke, Liver Cancer, Lung
Cancer, Malabsorption Syndrome, Melanoma, Multiple Myeloma (Kahler
Disease), Myocardial Infarction, Primary Sclerosing Cholangitis,
Prostate Cancer, Rheumatoid Arthritis, Sepsis and Staphylococcus Aureus
Septicaemia.
The latest report Integrin Beta 3 – Pipeline Review, H1 2019, outlays
comprehensive information on the Integrin Beta 3 (Platelet Membrane
Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics, complete with
analysis by indications, stage of development, mechanism of action
(MoA), route of administration (RoA) and molecule type. It also reviews
key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein
IIIa or CD61 or ITGB3) targeted therapeutics development with respective
active and dormant or discontinued projects.
Scope
-
The report provides a snapshot of the global therapeutic landscape for
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) -
The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein
IIIa or CD61 or ITGB3) targeted therapeutics under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources -
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages -
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities -
The report reviews key players involved in Integrin Beta 3 (Platelet
Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and
enlists all their major and minor projects -
The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein
IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of
action (MoA), route of administration (RoA) and molecule type -
The report summarizes all the dormant and discontinued pipeline
projects -
The report reviews latest news and deals related to Integrin Beta 3
(Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted
therapeutics
Companies Mentioned
- BrightGene Bio-Medical Technology Co Ltd
- Celltrion Inc
- Factor Therapeutics Ltd
- Merck & Co Inc
- Pliant Therapeutics Inc
- SciFluor Life Sciences LLC
- Tasly Pharmaceutical Group Co Ltd
- Vascular Pharmaceuticals Inc
- Virtual Drug Development Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5p2vg1
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Hematological
Drugs